Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Top 16 From '16: Pink Sheet's Most Popular Stories

Executive Summary

Big developments, key biopharma trends, and other topics that most intrigued and impacted our readers in 2016.

You may also be interested in...



Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'

Pink Sheet’s Drug Review Profile looks at US FDA clinical memos opposing approval of Sarepta's Duchenne muscular dystrophy drug eteplirsen, revealing challenges patient advocates and agency face in transforming patient experiences into hard data that can be used for approvals.

Woodcock Tries To Calm US FDA Staff Fears About Trump

CDER Director's' video advises focusing on the work and "keeping our heads down."

Trump’s FDA Reform Agenda: Patient-Focused Approvals

A posting on the transition website takes a much milder tone than the GOP platform issued over the summer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119759

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel